Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosis

  • Protocol
  • Intervention

Authors

  • Wenjuan Li,

    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Jing Zhang,

    1. West China Second University Hospital, Sichuan University, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Liangzhi Xu,

    Corresponding author
    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    • Liangzhi Xu, Department of Obstetrics and Gynecology, West China Second University Hospital, West China Women's and Children's Hospital, No. 17, Section Three, Ren Min Nan Lu Avenue, Chengdu, Sichuan, 610041, China. liangzxu@126.com.

    Search for more papers by this author
  • Liulin Tang,

    1. West China Second University Hospital, West China Women's and Children's Hospital, Department of Obstetrics and Gynecology, Chengdu, Sichuan, China
    Search for more papers by this author
  • Xin Pan,

    1. The University of Newcastle, Mother and Baby Center, School of Medicine and Public Health, New Castle, New South Wales, China
    Search for more papers by this author
  • Taixiang Wu

    1. West China Hospital, Sichuan University, Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials, Chengdu, Sichuan, China
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To estimate the clinical benefits and harms of all SERMs for postmenopausal osteoporosis in both prevention (women without postmenopausal osteoporosis) and treatment (postmenopausal osteoporosis with or without clinical history of previous osteoporotic fractures).

The principle objective of this review is based on the following questions:

  1. Is the use of SERMs effective and safe for the prevention and treatment of postmenopausal osteoporosis?

  2. Are SERMs more effective and safer than other approved drugs for prevention and treatment of postmenopausal osteoporosis?

  3. Which type of SERMs is the most effective or safest?